Study Confirms Lebrikizumab's Safety and Effectiveness for Patients with Skin of Color and Eczema
A recent study confirms that lebrikizumab is safe and highly effective for patients with skin of color suffering from eczema, showing significant skin improvement and quality of life benefits.
Recent research published in the American Journal of Clinical Dermatology has demonstrated that lebrikizumab is both safe and effective for individuals with skin of color suffering from atopic dermatitis (AD). This open-label phase study involved 90 adolescents and adults with moderate-to-severe AD and Fitzpatrick skin phototypes IV to VI, primarily self-identifying as non-white. Participants received 250 mg of lebrikizumab via subcutaneous injection every two weeks over a 16-week period.
The study defined responders as those achieving a 75% improvement in the Eczema Area and Severity Index (EASI 75) or an Investigator's Global Assessment (IGA) score of 0/1 with at least a 2-point improvement. Those meeting these criteria received continued treatment every four weeks between weeks 16 and 24, whereas insufficient responders kept receiving biweekly doses.
Results showed significant clinical improvements: at 16 weeks, 69.2% of patients achieved EASI 75, 44.9% reached EASI 90, and 44.9% attained an IGA score of 0 or 1. Additionally, over 58% experienced notable itching relief. By week 24, these numbers increased, with 78.4% reaching EASI 75 and 54.1% attaining IGA 0/1. Patients with darker skin types (phototypes V and VI) had particularly high response rates, with over 88% achieving EASI 75.
An important observation was the reduction in hyperpigmentation, reported in 64.4% of affected patients at week 24. Furthermore, more than half of the patients expressed high satisfaction with the treatment, citing improvements not only in skin condition but also in quality of life.
This study underscores lebrikizumab's potential as a safe and effective therapy tailored for diverse populations affected by eczema. Its ability to improve clinical symptoms and hyperpigmentation in skin of color highlights its significance in personalized dermatological care.
Source: https://medicalxpress.com/news/2025-08-lebrikizumab-efficacious-safe-patients-skin.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Are Hot Drinks a Risk Factor for Cancer? Insights from a Gut Health Expert
Recent research highlights the potential cancer risks associated with consuming very hot beverages. Learn how temperature and consumption habits can impact your health and what safety tips can help minimize risks.
Study Highlights Persistent Cervical Cancer Risks in Women Over 65 Due to HPV Infection
New research highlights the ongoing risk of cervical cancer in women aged 65 and over due to persistent high-risk HPV infections, calling for revised screening strategies worldwide.
Innovative Cancer Immunotherapy Brings New Hope for Advanced-Stage Patients
A groundbreaking Phase II clinical trial of PRL3-zumab reveals promising results in slowing disease progression in late-stage cancer patients unresponsive to traditional therapies, offering new hope for treatment-resistant cancers.
New Research Questions Safety of Paternal Valproate Use and Neurodevelopmental Risks
Recent research from Aarhus University challenges concerns about neurodevelopmental risks linked to paternal valproate use, questioning EMA's precautionary measures and highlighting the need for transparent, evidence-based policies.